Bausch Health Companies Inc.
BHCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeBausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. At a $1.80B market cap, Bausch Health Companies Inc. ranks as a small-cap company within healthcare. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Market Cap
$1.80B
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
1.15
EPS (TTM)
$-3.17
EPS (Fwd)
$4.22
ROE
—
ROA
5.9%
Cash
$1.30B
Total Debt
$20.80B
Free CF
$1.12B
52W Change
-23.4%
Annual Financials
Cash vs Debt
The company holds $1.30B in cash, though total debt stands at $20.80B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $1.12B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $8.12B (2022) to $10.27B (2025), reflecting a 26% increase over the period.
With a beta below 0.7, Bausch Health Companies Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Bausch Health Companies Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Bausch Health Companies Inc.'s trajectory.